Critical Path Initiative Sousan S. Altaie, Ph.D. Scientific Policy Advisor OIVD/CDRH.

Slides:

Advertisements

Similar presentations

Elizabeth Mansfield, PhD OIVD Public meeting July 19, 2010

Advertisements

The Drug Discovery Process

BME-IDEA Workshop, September 28, 2005

The Statisticians Role in Pharmaceutical Development

December 14, FDA Advisory Committee for Pharmaceutical Science Nonclinical Studies Subcommittee Efficient advancement to clinical trials Jack A.

FDA’s “Critical Path” Initiative Presentation to FDA Science Board Janet Woodcock, M.D. Acting Deputy Commissioner for Operations.

FDA’s Critical Path to New Medical Product Development Opportunities from the Center for Devices and Radiological Health Larry Kessler, Sc.D., Director.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.

REGULATORY ISSUES IN HIV CURE RESEARCH HIV Cure Research Training Curriculum Regulatory Issues Module by: Damon Deming, Ph.D. FDA Division of Antiviral.

Medical Devices Approval Process

Cancer Nanotechnology: New Opportunities for Targeted Therapies FDA Public Meeting October 10, 2006 Piotr Grodzinski, Ph.D. Director, Nanotechnology for.

Career Opportunities for PharmDs in the Pharmaceutical Industry: Research & Development.

Biomedical research methods. What are biomedical research methods? An integrated approach using chemical, mathematical and computer simulations, in vitro.

Research & Innovation Horizon societal challenge 1 Open Info Day Funding Opportunities for SMEs Horizon 2020 "Health, demographic change and wellbeing"

GLOBAL REGULATORY STRATEGY CONSIDERATIONS SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES SEPTEMBER 14-17, 2008 BOSTON, MA.

Stages of drug development

Critical Path Opportunities for Biologics Products Jesse L. Goodman, M.D. M.P.H. Director Kathryn M. Carbone, M.D. Associate Director for Research Center.

Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.

Medical Device Development Tools: FDA CDRH Pilot Program

Patient Safety and Medical Devices Sonia Swayze, RN, MA, C and Suzanne Rich, RN, MA, CT.

Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.

Stefan Franzén Introduction to clinical trials.

Understanding the Pre-IDE Program: FDA Perspective

The Science of Quality By Design Janet Woodcock, M.D. May 19, 2004.

1 FDA/CDRH Office of In Vitro Diagnostic Devices The Pre-IDE Process Sousan S. Altaie, Ph.D. Scientific Policy Advisor OIVD.

1 PAT and Biological Products Tom Layloff FDA-SGE Management Sciences for Health The views expressed here are those of the author and not necessarily.

1 Critical Path Research: Getting New Technology from Bench to Bedside A Device Perspective FDA Science Board November 5, 2004 Dan Schultz Director, CDRH.

FDA’s Draft LDT Framework & Personalized Medicine Update

CPTR Overview CPTR 2012 Workshop October 2-4, 2012.

The “Analysome” Unmet Need  Drug R&D requires validated biomarker assays  Information on such assays is available but is neither well coordinated nor.

RARE / ORPHAN DISEASES “ARE WE READY FOR THE CHANGE THAT WE NEED TO FIND EFFECTIVE TREATMENTS FOR ORPHAN DISEASE?”

Proposal for End-of-Phase 2A (EOP2A) Meetings Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence.

Regulatory Affairs and Adaptive Designs Greg Enas, PhD, RAC Director, Endocrinology/Metabolism US Regulatory Affairs Eli Lilly and Company.

DHHS / FDA / CDRH 1 FDA Summary CardioSEAL® STARFlex™ Septal Occlusion System with Qwik Load NMT Medical P000049/S3.

Clinical Writing for Interventional Cardiologists.

Center for Biologics Evaluation and Research, FDA Kathryn M. Carbone, M.D. Associate Director for Research.

Challenges of Bridging Studies in Biomarker Driven Clinical Trials May 19, MBSW Conference. Muncie, IN. Szu-Yu Tang, Chang Xu, Bonnie LaFleur May.

Current Plan for Critical Path Initiative Janet Woodcock, M.D. Acting Deputy Commissioner For Operations November 5, 2004.

FDA Office of Orphan Products Development

General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,

Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.

Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.

Second Meeting of the FDA/ACPS Process Analytical Technology: Closing Remarks Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Sciences.

Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.

1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD Barriers to Pharmaceutical Innovation Richard Laing EDM/PAR WHO.

Examining Drug Quality Regulation Douglas C. Throckmorton, MD Deputy Director Center for Drug Evaluation and Research Public Meeting on 21 CFR February,

COPYRIGHT ALL RIGHTS RESERVED. LEGAL DISCLOSURE. November 25, 2002 PRESENTATION TO: Public Hearing: FDA Regulation of Combination Products November.

Critical Path Public Docket: Overview for the FDA Science Board November 5, 2004.

FDA’s Patient Advocacy Programs: Patient Representative Program & Patient Network Andrea Furia-Helms, MPH James Valentine, MHS Office of Special Health.

Early Clinical Development Planning via Biomarkers, Clinical Endpoints, and Simulation: A Case Study to Optimize for Phase 3 Dose Selection (Musser et.

I farmaci innovativi in una prospettiva europea Giuseppe M.C. Rosano, MD, PhD Cardiovascular and Cell Sciences Research Institute, St George's University.

1 Promotion in Management and Research Tracks in Industry Magdalena Alonso-Galicia, PhD Cardiovascular Diseases Department Merck Research Laboratories.

CLI and Device Intervention Across the Pacific – An FDA View

The CRT of EFS Where We’ve Been and Where We’re Going

Contract Research organizations

FDA Division of Cardiovascular Devices

Jeff Shuren, MD, JD Center for Devices and Radiological Health U. S

FDA Perspective on Cardiovascular Device Development

BME-IDEA Workshop, September 28, 2005

Balancing Regulation and Innovation: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.

FDA Guidance for Industry and FDA Staff Summary of Public Notification of Emerging Postmarket Medical Device Signals (“Emerging Signals”) Effective: December.

Introduction of New Technology: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

Early Feasibility in the USA –An Academic View

Regulatory Considerations for Coronary Drug Coated Balloons – FDA View

FDA-CDRH in the Next Decade A Vision for Change

Erica Takai, PhD for Andrew Farb, M.D.

Challenges of Bridging Studies in Biomarker Driven Clinical Trials

Effectiveness Marlene Haffner, MD MPH Haffner Associates, LLC

Presentation transcript:

Critical Path Initiative Sousan S. Altaie, Ph.D. Scientific Policy Advisor OIVD/CDRH

What’s the FDA Critical Path Initiative? A serious attempt to modernize the medical products’ Critical Path and make product development more predictable and less costly

What’s the Critical Path? Basic Research Prototype Design or Discovery Clinical Development FDA Filing/ Approval & Launch Preparation Preclinical Development The journey from medical product candidate to full-scale production and marketing Critical Path Approval MarketApplication

Why FDA? Because of the tremendous benefit of bringing innovative products to the public fasterBecause of the tremendous benefit of bringing innovative products to the public faster Because our unique perspective understanding product development -- we see success, failure and missed opportunitiesBecause our unique perspective understanding product development -- we see success, failure and missed opportunities Because it will help us to develop guidance and standards that foster innovation and improve chances of successBecause it will help us to develop guidance and standards that foster innovation and improve chances of success

What do we want to do? Work together with companies, patient groups, academic researchers, and other stakeholders to Modernize, Develop and Disseminate solutions (tools) to the science hurdles affecting product development industry-wide

What are the Critical Path tools? The methods and techniques used for: –Assessment of Safety – how to predict if a potential product will be harmful? –Proof of Efficacy - how to determine if a potential product will have medical benefit? –Industrialization – how to manufacture a product at commercial scale with consistently high quality?

Some Critical Path tools… BiomarkersBiomarkers Bayesian statisticsBayesian statistics Animal models biomarkersAnimal models biomarkers Clinical trials designClinical trials design Computer simulationsComputer simulations Quality assessment protocolsQuality assessment protocols Post-market reportingPost-market reporting Suggestions???Suggestions???

Medical Device Critical Path Opportunities

Medical device Critical Path Medical devices are different DrugsDevices Pure molecules Complex components ToxicologyBiocompatibility Short half-life Durable Equipment Long market life Rapid product cycles Drug interactions Malfunction Wrong Drug / Dose User Error Clinically studied Bench studied Good Manufacturing Practices (cGMP) Quality Systems (ISO 9000)

Medical device areas of interest Device SAFETY tools Biocompatibility databaseBiocompatibility database Effects of products on diseased or injured tissuesEffects of products on diseased or injured tissues

Medical device areas of interest Device EFFECTIVENESS tools Surrogate endpoints for cardiovascular device trialsSurrogate endpoints for cardiovascular device trials Computer simulation modeling for implanted devicesComputer simulation modeling for implanted devices

Medical device areas of interest Device mass manufacture or INDUSTRIALIZATION toolsDevice mass manufacture or INDUSTRIALIZATION tools – Practice guidelines for follow-up of implanted devices –Validated training tools for devices with a known learning curve

Medical device Critical Path projects of interest New hepatitis assaysNew hepatitis assays –Serum panel to assess sensitivity and specificity Peripheral vascular stentsPeripheral vascular stents –Computer models of human physiology to test and predict failure (before animal and human studies) Intrapartum fetal diagnostic devicesIntrapartum fetal diagnostic devices –Clear “Regulatory Path” (with consensus from the Obstetrics community)

Medical device Critical Path projects of interest Surrogate markersSurrogate markers –Pathways for the statistical validation Permanently implanted devicesPermanently implanted devices –Practice guidelines for appropriate monitoring -- with Medical Specialty Organizations Neural tissue contacting materialsNeural tissue contacting materials –Extent of neurotoxicity testing

Are you interested? FDA Critical Path Docket and Opportunity List Update We are reviewing the comments send through the public docketWe are reviewing the comments send through the public docket –Areas that benefit from research and development of critical path evaluative tools We are compiling the National Critical Paths Opportunities ListWe are compiling the National Critical Paths Opportunities List –Almost there!

Contact us Web Address Web Addresshttp:// Open DocketOpen Dockethttp:// Docket # 2004N-0181 CDRH webpage (under news and events) provides links to the critical path white paper and docketCDRH webpage (under news and events) provides links to the critical path white paper and dockethttp:// Are you interested?